OYST
Oyster Point Pharma, Inc. [OYST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
OYST Stock Summary
In the News
OYST Financial details
Company Rating
-
Market Cap
0
Income
-188.97M
Revenue
19.58M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
303
Optionable
No
Shortable
Yes
Earnings
24 Feb 2023
P/E
-2.08
Forward P/E
-
PEG
-0.14
P/S
-
P/B
-13.5
P/C
-
P/FCF
-
Quick Ratio
2.81
Current Ratio
3.35
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-7.11
EPS next Y
-
EPS next Q
-
EPS this Y
37.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
19.13%
EPS Q/Q
-24.62%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-132%
ROE
-971%
ROC
-1.56%
Gross Margin
77%
Oper. Margin
-961%
Profit Margin
-1111%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.46-13.45
52W High
-
52W Low
-
RSI
-
Rel Volume
5
Avg Volume
417.56K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 417.56K
- Employee 303
- CEO Dr. Jeffrey Nau
- Headquarters Princeton,NEW JERSEY,US
- IPO Date 2019-10-31
-
Website
https://www.oysterpointrx.com 
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
